Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 16/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ME2 | P23368 | 1/20 | 0.51 |
| ▸ | ME1 | P48163 | 1/20 | 0.51 |
| ▸ | ME3 | Q16798 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19748346 | 0.89 | PANK3 (1.00) | PANK3KDM4ESMN1; SMN2ME2ME1 | |
| SCHEMBL26501471 | 0.87 | PANK3 (0.73) | PANK3KDM4ESMN1; SMN2ME2ME1 | |
| SCHEMBL21423733 | 0.85 | PANK3 (0.77) | PANK3 | |
| SCHEMBL26502420 | 0.85 | PANK3 (0.69) | PANK3KDM4ESMN1; SMN2ME2ME1 | |
| SCHEMBL21423846 | 0.84 | PANK3 (0.72) | PANK3KDM4ESMN1; SMN2ME2ME1 | |
| SCHEMBL26501319 | 0.83 | PANK3 (0.79) | PANK3 | |
| SCHEMBL26501618 | 0.82 | PANK3 (0.76) | PANK3KDM4ESMN1; SMN2ME2ME1 | |
| SCHEMBL21406436 | 0.81 | PANK3 (1.00) | PANK3ME2ME1ME3 | |
| SCHEMBL26027590 | 0.81 | ME2 (0.70) | PANK3KDM4ESMN1; SMN2ME2ME1 | |
| SCHEMBL21423847 | 0.80 | PANK3 (0.68) | PANK3KDM4EME2ME1ME3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | PANK3 1573/4885KDM4E 1116/4885SMN1; SMN2 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.